Remdesivir
Expression error: Unexpected < operator.Expression error: Unexpected < operator.Expression error: Unexpected < operator.
 | |
 | |
| Clinical data | |
|---|---|
| Pronunciation | /rɛmˈdɛsɪvɪər/ REM-dess-I-veer |
| Synonyms | GS-5734 |
| AHFS/Drugs.com | Professional Drug Facts |
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}} |
| Chemical and physical data | |
| Formula | C27H35N6O8P |
| Molar mass | 602.58 g·mol−1 |
| 3D model (JSmol) | |
Remdesivir is a broad-spectrum antiviral medication created by the biopharmaceutical company Gilead Sciences.[1] It was designed to treat Ebola.
As of 2020, remdesivir is being tested as a specific treatment for COVID-19. It is being used for the sickest of patients during the pandemic.[2] It may shorten the time it takes to recover from the infection.[3] Treatment is given by injection into a vein.[4][5]
On May 1, the United States Food and Drug Administration gave doctors permission to use remdesivir on patients with COVID-19. Ordinarily, the FDA would test remdesivir first to see if it worked on patients with COVID-19, but because of the COVID-19 pandemic, they told doctors they could start using the drug before the tests were finished.
In October 2020, the National Institutes of Health told the world the results of its tests: They studied 11,000 people and found that remdesivir did not help keep COVID-19 patients alive. Gilead and some scientists said the results of the tests might not be correct.[6]
Remdesivir Media
Activation of remdesivir into its active triphosphate metabolite
Synthesis of remdesivir in structural formulae
References
- ↑ Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. (April 2020). "Current pharmacological treatments for COVID-19: what's next?". British Journal of Pharmacology. 177 (21): 4813–4824. doi:10.1111/bph.15072. PMC 7264618. PMID 32329520.
- ↑ "Remdesivir EUA Letter of Authorization" (PDF). U.S. Food and Drug Administration (FDA). 1 May 2020. Retrieved 1 May 2020.
- ↑ Kolata, Gina; Baker, Peter; Weiland, Noah (29 April 2020). Remdesivir Shows Modest Benefits in Coronavirus Trial. https://www.nytimes.com/2020/04/29/health/gilead-remdesivir-coronavirus.html. Retrieved 3 May 2020.
- ↑ "Remdesivir". Drugs.com. Retrieved 30 April 2020.
- ↑ Mehta N, Mazer-Amirshahi M, Alkindi N (April 2020). "Pharmacotherapy in COVID-19; A narrative review for emergency providers". The American Journal of Emergency Medicine. 38 (7): S0735-6757(20)30263-1. doi:10.1016/j.ajem.2020.04.035. PMC 7158837. PMID 32336586. Archived from the original on 2020-05-02. Retrieved 2020-05-05.
- ↑ Gina Kolata; Katherine J. Wu (October 15, 2020). "Remdesivir Fails to Prevent Covid-19 Deaths in Huge Trial". New York Times. https://www.nytimes.com/2020/10/15/health/coronavirus-remdesivir-who.html?surface=home-discovery-vi-prg&fellback=false&req_id=164688077&algo=identity&imp_id=643601596&action=click&module=Science%20%20Technology&pgtype=Homepage. Retrieved October 21, 2020.
